SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

RESAPP HEALTH LIMITED (RAP)

Listed on ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

Shareholder links

Our website ranking of RAP: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Link Market Services, Level 12 QV1 Building 250 St Georges Terrace Perth WA 6000

Tel : +61 8 9211 6670 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000RAP5
Address: Level 12, 100 Creek Street Brisbane QLD 4000
Tel:  (07) 3724 0035 Fax: (08) 9218 8875

Date first listed: 12/01/2005
Company Secretary: Ms Nicki Farley
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Research and development of digital healthcare solutions for respiratory disease

The suspension of trading in the securities of ResApp Health Limited will be lifted immediately, following the release by RAP of an announcement.

30/10/2018

The company announces positive preliminary results from its SMARTCOUGHC-2 study, a double-blind, prospective study to evaluate the efficacy of the ResAppDx smartphone application for the diagnosis of childhood acute respiratory disease.

30/10/2018

Further to the request for Voluntary Suspension on 24 October 2018, ResApp Health Limited advises that it has received the US SMARTCOUGH-C-2 study results and is currently in the process of analysing these results. The Company anticipates that it will be in a position to release a full update to the market on Tuesday 30 October 2018.

29/10/2018

The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis.

24/10/2018

The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following receipt of an announcement.

09/08/2017

The company announced top line data from its multi-site double-blind prospective clinical study to investigate ResAppDx for the diagnosis for respiratory disease in infants and children using cough sounds.

09/08/2017

The securities of ResApp Health Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to its SMARTCOUGH-C study.

02/08/2017

The securities of ResApp Health Limited (the "Company") will be reinstated to official quotation as from 10 am EST on Tuesday, 14 July 2015, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules. 440,523,353 ordinary shares fully paid Security Code RAP

09/07/2015

name changed from Narhex Life Sciences Limited

08/07/2015

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    05/10/2017Brian Leedman875,885$0.074$64,512
    09/08/2017Chris Ntoumenopoulos1,000,000$0.073$72,822
    14/12/2016Brian Leedman-6,810,000$0.307$2,089,643
    14/03/2016Brian Leedman-500,000$0.305$152,271
    08/10/2015Adam Sierakowski-1,875,000$0.035$66,350

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Roger AstonNon Exec Chairman17/07/2015
    Tony KeatingManaging Director, CEO02/07/2015
    Chris NtoumenopoulosNon Exec Director22/01/2015
    Michael SteinNon Exec Director06/04/2020
    Robert RamsayNon Exec Director20/12/2013

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Nathan BuzzaNon Exec Director29/12/201731/03/2020
    Brian LeedmanExecutive Director22/02/201629/12/2017
    Adam SierakowskiNon Exec Director, Non Exec Director16/05/201322/03/2016
    Cyril D'SilvaExecutive Chairman16/05/201322/01/2015
    Peter ChristieChairman13/01/201120/12/2013
    David MandelDirector17/05/201020/12/2013
    Simon LillDirector13/01/201120/12/2013
    Ian ReynoldsDirector22/02/201330/04/2013
    Peter NashDirector07/10/200422/06/2012

    Date of first appointment, title may have changed.